AZD-2207

• Description :

  AZD-2207 is a cannabinoid receptor CB1 antagonist, known for its high lipophilicity. AZD-2207 has good intestinal permeability in the Caco-2 model and can be used in research related to type 2 diabetes and obesity[1].

• UNSPSC :

  12352005

• Target :

  Cannabinoid Receptor

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Field of Research :

  Metabolic Disease

• Smiles :

  O=C(C1=C(C)N(C2=CC=C(C=C2)OS(=O)(CCC(F)(F)F)=O)C(C3=C(Cl)C=C(Cl)C=C3)=N1)NN4CCCCC4

• Molecular Formula :

  C25H25Cl2F3N4O4S

• Molecular Weight :

  605.46

• References & Citations :

  [1]Christer Tannergren, et al. Biopharmaceutic Profiling of Salts to Improve Absorption of Poorly Soluble Basic Drugs. J Pharm Sci. 2016 Nov;105 (11) :3314-3323.|[2]Jin Hee Kim, et al. Rengyolone inhibits inducible nitric oxide synthase expression and nitric oxide production by down-regulation of NF-kappaB and p38 MAP kinase activity in LPS-stimulated RAW 264.7 cells. Biochem Pharmacol. 2006 Apr 14;71 (8) :1198-205.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  CB1

• CAS Number :

  [866598-45-0]